// App-Quantinova.ai

: Bimekizumab versus secukinumab in plaque psoriasis: Reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial

Researchers

Presenter

  • Matthias Augustin

Principal Investigators

  • Melinda Gooderham

  • Alice B. Gottlieb

  • Stefan Beissert

  • Nicola Tilt

  • Christopher Cioffi

  • Natalie Nunez Gomez

  • Valerie Ciaravino

  • April Armstrong

Medical Centers

  • Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg, Hamburg, Germany

  • Skin Centre for Dermatology, Probity Medical Research, Peterborough, and Queen’s University, Kingston, ON, Canada

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Dept of Dermatology, University-Hospital Carl Gustav Carus, Dresden, Germany

  • UCB Pharma, Slough

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Monheim, Germany

  • UCB Pharma, Colombes, France

  • Keck School of Medicine of USC, Nephrology, Los Angeles, CA, USA

Locations

  • Germany

  • France

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved